1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,300 | 1,370 | 05.10. | |
| 1,290 | 1,370 | 04.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID | 359 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30... ► Artikel lesen | |
| 27.09. | NANOVIRICIDES, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 26.09. | NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including "Trojan Horse" Drugs | 481 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that... ► Artikel lesen | |
| 26.08. | MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX | 506 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 26, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it... ► Artikel lesen | |
| 19.08. | NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections | 725 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 19, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 09.08. | NanoViricides extends executive contracts, grants stock | 1 | Investing.com | ||
| 09.08. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics | 520 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update... ► Artikel lesen | |
| 01.08. | "NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides | 549 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate... ► Artikel lesen | |
| 24.07. | COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides | 606 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today reminds the strong... ► Artikel lesen | |
| 11.07. | A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides | 571 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development... ► Artikel lesen | |
| 24.06. | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides | 567 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum... ► Artikel lesen | |
| 20.06. | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model | 656 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / June 20, 2024 / NanoViricides, Inc. (NYSE AmerIcan.:NNVC) (the "Company"), a clinical stage company and global leader in broad-spectrum antiviral nanomedicines, reports that... ► Artikel lesen | |
| 11.06. | NanoViricides, Inc.: Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect | 531 | ACCESSWIRE | A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 11, 2024 / NanoViricides... ► Artikel lesen | |
| 04.06. | NanoViricides, Inc.: The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect | 519 | ACCESSWIRE | A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT / ACCESSWIRE / June 4, 2024 / NanoViricides... ► Artikel lesen | |
| 29.05. | SMLR, NNVC and QBTS are among premarket gainers | 40 | Seeking Alpha | ||
| 29.05. | NanoViricides, Inc.: A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More | 555 | ACCESSWIRE | Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum... ► Artikel lesen | |
| 23.05. | NanoViricides, Inc.: NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc. | 583 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it has engaged... ► Artikel lesen | |
| 20.05. | NanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure | 728 | ACCESSWIRE | NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company")... ► Artikel lesen | |
| 15.05. | NanoViricides GAAP EPS of -$0.16 | 2 | Seeking Alpha |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 53,50 | +4,49 % | Formycon: FDA-Zulassung für FYB202 | Formycon hat für ihr Stelara-Biosimilar FYB202/Otulfi nach dem grünen Licht der Europäischen Kommission zur Behandlung schwerwiegender inflammatorischer Erkrankungen auch die Zulassung in den USA erhalten.... ► Artikel lesen | |
| ONTO INNOVATION | 188,00 | -1,57 % | P/E Ratio Insights for Onto Innovation | ||
| KOPIN | 0,704 | +2,03 % | Kopin Corporation: Kopin to Exhibit at VISION 2024, Stuttgart, Germany | Kopin to Demo New SXGA-R15 Microdisplay Assembly for 3D Automated Optical Inspection (3D AOI)
Kopin Corporation (NASDAQ: KOPN) a leading provider of application-specific optical systems and high-performance... ► Artikel lesen | |
| GAUZY | 8,770 | -3,63 % | Gauzy Ltd. Announces Preliminary Revenue Ranges, Demonstrating Strong Double-Digit Growth for the Second Quarter and First Half 2024 that Exceeded Expectations | TEL AVIV, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control solutions, today provided preliminary unaudited... ► Artikel lesen | |
| NANOFOCUS | 1,210 | -3,20 % | NanoFocus holt sich mehr als 2 Millionen Euro bei Anlegern | NanoFocus meldet die komplette Platzierung der jüngst beschlossenen Kapitalerhöhung. "Sämtliche Neuen Aktien wurden von Aktionären der NanoFocus AG im Rahmen ihres Bezugsrechts bzw. des eingeräumten... ► Artikel lesen | |
| ACACIA RESEARCH | 3,980 | +1,53 % | Acacia Research Reports Second Quarter 2024 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company") today reported financial results for the three and six months ended June 30, 2024. The Company... ► Artikel lesen | |
| NVE | 69,50 | -1,42 % | Dividendenbekanntmachungen (29.07.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACOMO NV NL0000313286 - 0,4 EUR ASML HOLDING NV NL0010273215 - 1,52 EUR ASML HOLDING NV NY USN070592100 1,6568 USD 1,5261 EUR AVAX... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,510 | -0,97 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| LEHNER INVESTMENTS | 0,015 | 0,00 % | EQS-DD: LEHNER INVESTMENTS AG: RIMIVY LTD, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.07.2024 / 16:36... ► Artikel lesen | |
| RIBER | 2,550 | -1,92 % | RIBER receives order to equip an autonomous pilot line for the design and manufacturing of optical devices in Europe | RIBER receives order to equip an autonomous pilot line for the design and manufacturing of optical devices in Europe Bezons (France), September 30, 2024 - 8:00 am (CET) - RIBER, the global leader... ► Artikel lesen | |
| GOMSPACE | 0,380 | 0,00 % | GOMSPACE A/S: GomSpace signs 3.6 MSEK standard platform contract with UK university partnership | ||
| REGION GROUP | 1,386 | -0,69 % | REGION GROUP: Appendix 4G and FY24 Corporate Governance Statement | ||
| XTPL | 25,200 | +7,92 % | EQS-News: XTPL S.A.: XTPL with PLN 5.6 million of commercial sales in H1 2024 and progress on industrial projects - press release | Issuer: XTPL S.A.
/ Key word(s): Half Year Results/Interim Report
XTPL with PLN 5.6 million of commercial sales in H1 2024 and progress on industrial projects - press release... ► Artikel lesen | |
| NANOFORM FINLAND | 1,560 | +0,91 % | NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT | HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development... ► Artikel lesen | |
| INSPLORION | 0,061 | -47,53 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.10.2024 | Das Instrument YHAA US9846271099 YAMAHA CORP.SP.ADR/1 O.N. EQUITY wird ex Kapitalmassnahme gehandelt am 02.10.2024 The instrument YHAA US9846271099 YAMAHA CORP.SP.ADR/1 O.N. EQUITY is traded ex capital... ► Artikel lesen |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell -1,55 % bei einem Aktienkurs von 1,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.
